Regenerative medicine company Juventas Therapeutics is touting the results from 12-month data of a phase 1 clinical trial of heart failure patients.At 12 months, heart failure patients treated with the company’s stem cell therapy showed “significant” improvements in two key measures — a six-minute distance-walking test, as well as the Minnesota Living with Heart Failure [...]

A phase 1 clinical trial has shown that Juventas Therapeutics‘ regenerative medicine therapy provides clinical benefit to heart failure patients.Phase 1 trials generally focus on safety, so the indication of clinical benefit is an encouraging sign for Cleveland-based Juventas. “We are excited to see strong signs of efficacy across multiple clinical parameters,” CEO Rahul Aras [...]

Cleveland Clinic spinoff Juventas Therapeutics has successfully completed a phase 1 clinical trial of its regenerative medicine technology in heart failure patients.Cleveland-based Juventas’ technology, JVS-100, works by recruiting stem cells from the bone marrow to create new blood vessels. In addition to heart failure patients, the company is investigating the treatment of patients suffering [...]

SironRX hopes to raise $2.5 million, which it would use to fund a Phase 2 clinical trial of its wound-healing technology.

Regenerative medicine company Juventas Therapeutics Inc. has received regulatory approval to begin a Phase 2 clinical trial of critical limb ischemia patients.

Updated 4:36 p.m.Cleveland Clinic Innovations — the corporate venturing arm of the nation’s top heart hospital — is entering its second decade with a first-of-its-kind venture ranking, a brand-new incubator building and a growing portfolio of spin-out companies.AdvertisementPerhaps most impressive, those companies — 33 in all — have attracted more than $340 million in follow-on [...]

Clinical-stage regenerative medicine company Juventas Therapeutics Inc.–a Cleveland Clinic spin-off initially named AccelleRX–has started enrolling patients in a Phase 1 clinical trial to evaluate the safety and efficacy of its leading stem cell factor for treating heart failure.In preclinical studies of heart failure in pigs, JVS-100, as the factor is known, significantly increased cardiac function [...]

The money will push two stem-cell technologies deeper into clinical trials and create Ohio’s first Pluripotent Stem Cell Facility.